--(BUSINESS WIRE)--Merganser Biotech is a privately funded biotech company focused on the evaluation of hepcidin mimetic peptides for the treatment of rare hematological and iron overload diseases. Target indications for lead compound (M012) include Beta Thalassemia, Polycythemia Vera, Hemochromatosis and Acute Sever Infections caused by siderophilic pathogens in patients with iron overload. Merganser Biotech is backed by a syndicate of life sciences investors that includes the Novartis Venture Fund, Frazier Healthcare Partners, Sutter Hill Ventures and Osage University Partners.
| Company: | Merganser Biotech | |||||
| Headquarters Address: | 1004 W. 9th Avenue | |||||
| King of Prussia, PA 19406 | ||||||
| Main Telephone: | 978-760-3566 | |||||
| Website: | ||||||
| Type of Organization: | Private | |||||
| IRPR | ||||||
| Industry: | Biotechnology | |||||
| Key Executives: | CEO: Brian MacDonald | |||||
| COO: Remy Sukhija | ||||||
| SVP, Development: Gene Merutka | ||||||
| Investor Relations | ||||||
| Contact: | Remy Sukhija | |||||
| Phone: | 978-760-3566 | |||||
| Email: | ||||||
| Public Relations | ||||||
| Contact: | Remy Sukhija | |||||
| Phone: | 978-760-3566 | |||||
| Email: | ||||||
Help employers find you! Check out all the jobs and post your resume.
